Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | FABP1 | P07148 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | LIFR | P42702 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3996233 | 1.00 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL29459634 | 1.00 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL3996237 | 1.00 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL14601398 | 0.95 | NR1H4 (0.91) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL2491489 | 0.92 | NR1H4 (0.85) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL2491490 | 0.92 | NR1H4 (0.85) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL12932245 | 0.90 | NR1H4 (0.81) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL5354375 | 0.89 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL16448984 | 0.88 | NR1H4 (0.91) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL13805380 | 0.88 | NR1H4 (0.79) | NR1H4MEN1FABP1THRBLIFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| CN-120114444-A | Application of GW4064 in treatment of polycystic ovary syndrome | 首都医科大学附属北京妇产医院 | 2025-06-10 | — | — | CN | claimed |
| US-20250152531-A1 | INHIBITORS OF AUTOPHAGY AND DCAR-1 AS NOVEL ANTHELMINTIC AGENTS | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES | 2025-05-15 | — | — | US | claimed |
| CN-119569671-A | Application of GW4064 in preparation of anti-porcine reproductive and respiratory syndrome virus drugs | 华南农业大学 | 2025-03-07 | — | — | CN | claimed |
| US-20250073234-A1 | COMBINATION THERAPIES INCLUDING PARP1 INHIBITORS | CORNELL UNIVERSITY | 2025-03-06 | — | — | US | claimed |
| EP-4090327-B1 | USE OF FXR AGONISTS FOR TREATING AN INFECTION BY HEPATITIS D VIRUS | INST NAT SANTE RECH MED (FR) | 2025-03-05 | — | — | EP | claimed |
| US-12233036-B2 | Inhibitors of autophagy and DCAR-1 as novel anthelmintic agents | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) | 2025-02-25 | — | — | US | claimed |
| CN-119303098-A | Application of FXR agonist combined PD1/PD-L1 monoclonal antibody in preparation of anti-liver cancer drugs | 内蒙古医科大学 | 2025-01-14 | — | — | CN | claimed |
| WO-2024259358-A2 | MODULATION OF FUSOBACTERIUM NUCLEATUM SUBSPECIES ANIMALIS CLADE 2 MICROBES | FRED HUTCHINSON CANCER CENTER (US) | 2024-12-19 | — | — | WO | claimed |
| US-20240335497-A1 | PULSE PROTEIN-BASED COMPOSITION FOR ACTIVATING THE SYNTHESIS OF FGF19 | ROQUETTE FRERES (FR) | 2024-10-10 | — | — | US | claimed |
| US-11541032-B2 | Composition containing sumo inhibitor and application | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2023-01-03 | — | — | US | claimed |
| EP-4090327-A1 | USE OF FXR AGONISTS FOR TREATING AN INFECTION BY HEPATITIS D VIRUS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-11-23 | — | — | EP | claimed |
| WO-2022229302-A1 | STRONG POTENTIATION OF TLR3 AGONISTS EFFECTS USING FXR AGONISTS AS A COMBINED TREATMENT | ENYO PHARMA (FR) | 2022-11-03 | — | — | WO | claimed |
| WO-2022192042-A2 | REGENERATION OF MAMMALIAN TISSUES USING SYNTHETIC IMMODULINS | MASCARENHAS DESMOND (US) | 2022-09-15 | — | — | WO | claimed |
| CN-114945361-A | Use of FXR agonists for the treatment of hepatitis delta virus infection | 法国国家卫生及研究医学协会 | 2022-08-26 | — | — | CN | claimed |
| US-20220257612-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE | THE TRUSTEES OF INDIANA UNIVERSITY | 2022-08-18 | — | — | US | claimed |
| CN-110404073-B | Methods and pharmaceutical compositions for treating hepatitis B virus infection | 国家医疗保健研究所 | 2022-08-16 | — | — | CN | claimed |
| WO-2022152770-A1 | SYNERGISTIC EFFECT OF A FXR AGONIST AND IFN FOR THE TREATMENT OF HBV INFECTION | ENYO PHARMA (FR) | 2022-07-21 | — | — | WO | claimed |
| WO-2022124795-A1 | PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING METABOLIC OR CHOLESTATIC LIVER DISEASE, COMPRISING TRAMETINIB AND SELECTIVE FARNESOID X RECEPTOR AGONIST | 주식회사 스탠다임 | 2022-06-16 | — | — | WO | claimed |
| EP-3733207-B1 | COMPOSITION CONTAINING SUMO INHIBITOR AND ITS APPLICATION | UNIV CHINA PHARMA (CN) | 2022-05-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220257612-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE | BCHE, GOT2, GOT1 | NR1H4 53/4885MEN1 4065/4885FABP1 43/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | NR1H4 80/4885MEN1 962/4885FABP1 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.